Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Current Assets (2016 - 2025)

Sangamo Therapeutics has reported Current Assets over the past 16 years, most recently at $35.8 million for Q4 2025.

  • Quarterly results put Current Assets at $35.8 million for Q4 2025, down 30.68% from a year ago — trailing twelve months through Dec 2025 was $35.8 million (down 30.68% YoY), and the annual figure for FY2025 was $35.8 million, down 30.68%.
  • Current Assets for Q4 2025 was $35.8 million at Sangamo Therapeutics, down from $44.1 million in the prior quarter.
  • Over the last five years, Current Assets for SGMO hit a ceiling of $606.9 million in Q1 2021 and a floor of $35.8 million in Q4 2025.
  • Median Current Assets over the past 5 years was $153.6 million (2023), compared with a mean of $217.1 million.
  • Biggest five-year swings in Current Assets: skyrocketed 63.62% in 2021 and later crashed 74.89% in 2024.
  • Sangamo Therapeutics' Current Assets stood at $398.8 million in 2021, then fell by 24.69% to $300.3 million in 2022, then crashed by 68.59% to $94.3 million in 2023, then tumbled by 45.2% to $51.7 million in 2024, then crashed by 30.68% to $35.8 million in 2025.
  • The last three reported values for Current Assets were $35.8 million (Q4 2025), $44.1 million (Q3 2025), and $49.9 million (Q2 2025) per Business Quant data.